Top Story Today
Moderna's mRNA Flu Vaccine Just Shattered the One-Hit Wonder Myth
The FDA approved Moderna's mFLUSIVA, the first mRNA flu vaccine ever, clearing it for adults 50 and older. In a head-to-head trial of over 40,800 patients, it beat an existing flu shot by 26.6%, and the advantage jumped to nearly 48% for serious outcomes like ER visits and hospitalizations. Wall Street barely flinched because Moderna missed the 2026 flu contracting cycle; meaningful revenue won't arrive until the second half of 2027. But the real payoff isn't commercial. The FDA has now approved mRNA vaccines for three different diseases, establishing a regulatory pattern that de-risks every mRNA program in the industry's pipeline.
Why it matters: With mRNA now approved across COVID, RSV, and influenza, regulators have established a clear precedent that the technology is a legitimate pharmaceutical platform, not an emergency tool. That changes the risk calculus for dozens of pipeline programs across oncology, infectious disease, and beyond.
Read more →Clinical and Regulatory
The First Drug That Fixes Narcolepsy Instead of Just Masking It
The FDA approved Takeda's Orzeyful, the first drug to target the root cause of narcolepsy type 1 by activating orexin receptors that lost their natural signal. About 70% of patients reported no significant cognitive difficulties by week 12, versus just 15% on placebo. The most ironic side effect? Insomnia. Pricing estimates range from $142,000 to over $250,000 per year, with peak sales projected at $2 billion to $3 billion.
Read more →The CDC Finally Has a Permanent Director. The Vaccine Question Looms Large.
The Senate confirmed Erica Schwartz as CDC director on a near party-line 51-44 vote, ending nearly a year without permanent leadership. Her resume spans Hurricane Katrina, Ebola, and COVID testing infrastructure, but the real test is whether she'll push back against HHS Secretary RFK Jr. on vaccine policy. For vaccine makers, CDC guidance drives real-world adoption and revenue.
Read more →Deals and Strategy
Lilly Pours $750M Into Factories Because the Real GLP-1 War Is About Pens, Not Pills
Eli Lilly is spending $750 million to expand KwikPen manufacturing with contract partner Resilience, adding 400 jobs and targeting full operations by early 2027. The partnership has already produced over 150 million doses. With Lilly's total U.S. manufacturing commitments exceeding $50 billion since 2020, the company is betting that supply, not science, will be the limiting factor in the GLP-1 market.
Read more →A Cancer Biotech Just Bought a Lung Drug Company (and the Math Is Actually Clever)
Zymeworks is acquiring Theravance Biopharma for $929 million, picking up steady cash flows from the COPD drug YUPELRI and a $100 million TRELEGY milestone expected in early 2027. The financing trick: a $350 million non-recourse loan backed solely by YUPELRI profit-share cash flows, keeping Zymeworks' balance sheet protected. The goal is letting someone else's inhaler fund a decade of cancer research.
Read more →BioCryst Shut Down Its 40-Year-Old Lab to Become a Deal Shop
BioCryst is closing its internal drug discovery operation and pivoting entirely to licensing and acquisitions. Unlike most biotechs that cut R&D out of desperation, BioCryst is profitable: Q2 revenue hit $218.3 million with $98.5 million in operating profit. Full-year guidance was raised to $690-715 million. The kitchen is closed; now the question is whether they have taste.
Read more →Science and Discovery
An AI-Designed Parkinson's Drug Just Got Cleared for Human Trials on Three Continents
Insilico Medicine's ISM8969, a molecule designed entirely by generative AI, received IND clearance in China for Parkinson's disease and is already dosing healthy volunteers in Australia. The oral drug targets the NLRP3 inflammasome to calm neuroinflammation. It's one of the first AI-originated drugs to tackle neurodegeneration, though Parkinson's has humbled far more compounds than it has crowned.
Read more →The Gene Therapy That Silences Genes Without Touching Your DNA
Epicrispr fully enrolled and dosed all 12 patients in the first-ever epigenetic editing trial for muscular dystrophy. EPI-321 uses a deactivated CRISPR protein to re-silence the toxic DUX4 gene in FSHD patients, leaving DNA completely intact. Early signals show improved strength and lean muscle volume. More data are expected at the World Muscle Society congress in September.
Read more →Two Struggling Biotechs Merged Into a $125M Fibrosis Bet
Skye Bioscience and Redx Pharma are combining to form Fibrx Therapeutics with $125 million in financing, targeting fibrosis (a disease area with almost no approved treatments). The lead asset, RXC008, has FDA Fast Track designation for fibrostenotic Crohn's disease. The catch: original Skye shareholders got diluted down to just 5.38% of the new company.
Read more →